行业跟踪:PCOS妊娠管理中西合璧，孕育新机

Investment Rating - The report does not explicitly state an investment rating for the gynecological industry or Polycystic Ovary Syndrome (PCOS) treatments Core Insights - Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder among women of reproductive age, characterized by irregular menstruation, hyperandrogenism, and ovulatory dysfunction, with potential metabolic abnormalities such as obesity and insulin resistance [4][10] - The prevalence of PCOS among reproductive-age women in China ranges from 5% to 10%, influenced by diagnostic criteria and regional factors [4][6] - Current treatment options for PCOS include hormonal therapies, insulin sensitizers, and lifestyle modifications, with a focus on managing symptoms and improving fertility outcomes [15][16] Summary by Sections Clinical Manifestations and Epidemiology - PCOS is associated with symptoms such as irregular menstruation, anovulation, hirsutism, and metabolic issues like obesity and insulin resistance [3][4] - Epidemiological studies indicate varying prevalence rates across different regions in China, with notable figures such as 12.8% in Tianjin among adolescents [6] Impact on Fertility - PCOS is a leading cause of anovulatory infertility, with complications including endometrial hyperplasia and increased miscarriage risk due to hormonal imbalances and metabolic dysfunctions [10][11] - Factors contributing to increased miscarriage rates in PCOS patients include obesity, insulin resistance, and hormonal dysregulation [11] Treatment Options - Key medications for PCOS treatment include progestins, oral contraceptives, insulin sensitizers like Metformin, and ovulation induction agents [15] - The report highlights the importance of insurance coverage for these treatments, with various classifications under the national health insurance system [15] Research Progress - Current research focuses on molecular mechanisms of PCOS, including iron death, circadian rhythms, and genetic factors influencing insulin resistance [16] - There is an emphasis on personalized medicine approaches and the integration of traditional Chinese medicine with modern treatments to enhance patient outcomes [16] Implications for Industry Development - The report suggests that the combined treatment strategies for PCOS can guide pharmaceutical companies in developing targeted therapies that address both reproductive and metabolic health [21]